This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Regeneron Highlights EYLEAA® (aflibercept) Injection Data To Be Presented At American Academy Of Ophthalmology Annual Meeting

TARRYTOWN, N.Y., Nov. 12, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from several studies of EYLEA ® (aflibercept) Injection will be presented during the annual meeting of the American Academy of Ophthalmology (AAO) to be held November 16-19 in New Orleans.  EYLEA presentations will be featured during the AAO scientific sessions ( November 16-19), as well as during the Retina Subspecialty Days ( November 15-16).

During the Retina Subspecialty Days, detailed results from the Phase 3 VIBRANT study of EYLEA in Macular Edema following BRVO will be presented for the first time.  Retinal vein occlusion is a common cause of vision loss in the elderly and the second most frequent major retinal vascular disease.(1)       

"Regeneron continues to study EYLEA across a range of eye diseases where Vascular Endothelial Growth Factor (VEGF) has demonstrated a role in disease development," said Robert Vitti, M.D., Vice President, Clinical Sciences, Ophthalmology, at Regeneron.  "The presentations at this year's AAO meeting reflect our commitment to continually provide data from the full spectrum of on-going research with EYLEA."

Abstracts include:

Friday, November 15 (Retina Subspecialty Day)
  • Intravitreal aflibercept for macular edema due to branch retinal vein occlusion:  24 week results of the VIBRANT study
    • Presenting author: W. Lloyd Clark, M.D.
    • Oral presentation at 1:51 p.m.; Morial Convention Center, Great Hall
  • Intravitreal aflibercept injection for diabetic macular edema: 12 month results of VISTA-DME and VIVID DME
    • Presenting author: Diana Do, M.D.
    • Oral presentation at 1:58 p.m.; Morial Convention Center, Great Hall
  • VEGF Trap-Eye (VIEW) sub-analysis: Influence of anatomic characteristics on outcomes
    • Presenting author: John Kitchens, M.D.
    • Oral presentation at 3:59 p.m.; Morial Convention Center, Great Hall

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,102.38 -272.38 -1.66%
S&P 500 1,921.22 -29.91 -1.53%
NASDAQ 4,683.9190 -49.5780 -1.05%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs